Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis | Zendy

Rong Tang | Zendy; Qingcai Meng | Zendy; Wei Wang | Zendy; Chen Liang | Zendy; Jie Hua | Zendy; Jin Xu | Zendy; Xianjun Yu | Zendy; Si Shi | Zendy

Open Access

Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis

Author(s) -

Rong Tang,

Qingcai Meng,

Wei Wang,

Chen Liang,

Jie Hua,

Jin Xu,

Xianjun Yu,

Si Shi

Publication year - 2021

Publication title -

gland surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.643

H-Index - 22

eISSN - 2227-8575

pISSN - 2227-684X

DOI - 10.21037/gs-21-16

Subject(s) - folfirinox , medicine , gemcitabine , oncology , hazard ratio , confidence interval , cochrane library , pancreatic cancer , meta analysis , odds ratio , irinotecan , chemotherapy , cancer , colorectal cancer

The benefits of neoadjuvant chemotherapy (NCT) in pancreatic cancer (PC) have been realized and gradually accepted. FOLFIRINOX and gemcitabine and nab-paclitaxel (GA) are the two most widely used regimens for PC NCT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog